Engineered T-cell therapy using a CD19-specific chimeric antigen receptor (CD19-CAR) is a promising strategy for the treatment of advanced B-cell malignancies. Gene transfer of CARs to T-cells has widely relied on retroviral vectors, but transposon-based gene transfer has recently emerged as a suitable nonviral method to mediate stable transgene expression. The advantages of transposon vectors compared with viral vectors include their simplicity and cost-effectiveness. We used the Tol2 transposon system to stably transfer CD19-CAR into human T-cells. Normal human peripheral blood lymphocytes were co-nucleofected with the Tol2 transposon donor plasmid carrying CD19-CAR and the transposase expression plasmid and were selectively propagated on NIH3T3 cells expressing human CD19. Expanded CD3 + T-cells with stable and high-level transgene expression (~95%) produced interferon-γ upon stimulation with CD19 and specifically lysed Raji cells, a CD19
INTRODUCTION
Adoptive immunogene therapy with T-cells expressing chimeric antigen receptors (CARs) is a promising approach for the treatment of advanced malignancies. CARs are composed of an extracellular single chain fragment of variable region fused to one of the two intracellular lymphocyte signaling domains, CD28 or 4-1BB (CD137), coupled with CD3ζ to mediate T-cell activation. 1 T-cells transduced with CAR-expressing vectors can recognize and kill tumor cells that express tumor-associated antigens such as CD19 in a human leukocyte antigen-independent manner. In early-phase clinical trials, the adoptive transfer of CD19-specific CAR (CD19-CAR)-transduced T-cells was found to cause anti-tumor effects in patients with chemorefractory CD19 + B-cell malignancies. 2 The gene transfer of CARs into T-cells has mainly been achieved using retroviral vectors. However, DNA transposon-based gene transfer has emerged as an appealing alternative, because transposon vectors are easier and less expensive to manufacture than retroviral vectors. 3 Transposon vectors work via a cut-andpaste mechanism called transposition, whereby transposon DNA containing the gene of interest is integrated into chromosomal DNA by a transposase.
Tol2 is an active transposon derived from the medaka fish (Oryzias latipes). 3, 4 It is active in a variety of vertebrate species and has been used for gene transfer in mammalian cells. 4, 5 Tol2 has a fairly large cargo capacity; it can carry a total of around 200 kb and~1 0 kb without reducing its transpositional activity. 6, 7 Recently, the piggyBac (PB) transposon was shown to have a cargo capacity of 150 kb. 8 Transposase itself can act as a transposition inhibitor when it exceeds a threshold concentration, enabling it to limit transposon activity in a phenomenon called overproduction inhibition (OPI). The Sleeping Beauty (SB) transposon undergoes OPI, whereas Tol2 and PB transposons exhibit limited OPI. 9 Unlike SB and PB transposons that specifically integrate at TA or TTAA sequences, respectively, Tol2 does not appear to have a specific preferential target sequence. 3 In the present study, we investigated whether the Tol2 transposon system could mediate the stable transfer of CD19-CAR to primary human T-cells. We show that Tol2-engineered T-cells efficiently and stably expressed CD19-CAR and exhibited CD19-dependent anti-tumor effects in vitro and in a mouse xenograft model. Our results demonstrate for the first time that the Tol2 transposon system can be used to stably express CD19-CAR in engineered T-cells for the treatment of B-cell malignancies.
RESULTS AND DISCUSSION
Transposons are promising nonviral vectors for human gene therapy. They have significantly higher integration efficiencies than electro-transferred naked DNA plasmids. Moreover, compared with retroviral vectors, transposons offer several advantages, such as low immunogenicity, simplicity of use and low manufacturing costs. The SB and PB transposon systems have also been used to stably introduce CD19-CARs into human Tcells, 10, 11 while the SB system recently formed part of a human clinical trial involving CAR-based T-cell therapy for B-cell malignancies. 12 In the present study, we generated a Tol2 transposon construct carrying the CD19-CAR gene (pTol2-CD19-CAR) (Figure 1 ). To evaluate whether the Tol2 transposon system could be used for CD19-CAR transfer, human peripheral blood lymphocytes (PBLs) were transfected with pTol2-CD19-CAR in the presence or absence of the Tol2 transposase expression plasmid (pCAGGS-mT2TP) (Figure 1 ). Transfected T-cells were propagated on NIH3T3 cells expressing CD19 (3T3/CD19).
We analyzed the surface expression of CD19-CAR in transfected T-cells by flow cytometry. On day 21 of the culture, CD19-CAR + CD3
+ T-cells constituted approximately 95% of cultures transfected with both Tol2 transposon and transposase plasmids, whereas CD19-CAR expression was very low (2%) in T-cells transfected with the transposon alone (Figure 2a) . We also confirmed CD19-CAR expression in T-cells co-transfected with Tol2 transposase by western blotting (Figure 2b ). Co-transfected T-cells showed an approximately 29-fold expansion within 3 weeks, while T-cells transfected with transposon alone did not grow ( Figure 2c ). We next examined the immunophenotypes of expanded T-cells by flow cytometry. On day 21, these T-cells were positive for CD3 (99%), CD4 (61%) and CD8 (34%) after ex vivo expansion with antigen stimulation (Supplementary Figure S1) . A CD4-dominant population was also previously observed in the results of SB-and PB-based T-cell gene transfer with CD19-CAR, 10,13 while Saito et al.
14 recently showed a CD8-dominant culture method after PB-based T-cell gene transfer with CD19-CAR. When specific T-cell subsets of engineered T-cells were analyzed in the present study, both CD45RO + CD62L
+ central memory and CD45RO + CD62L − effector memory phenotypes were present (Supplementary Figure S1) . These results show that large numbers of T-cells with stable and high-level transgene expression were generated by Tol2-mediated gene transfer and ex vivo expansion.
To examine whether stable CD19-CAR expression in Tol2-engineered T-cells was caused by genomic integration of the transposon, we measured the transgene copy number relative to the copy number of the interferon (IFN)-γ gene as a reference using real-time quantitative PCR. At 21 and 29 days posttransduction, the calculated transgene copies per T-cell were 1.75 ± 0.1 and 1.53 ± 0.6 (mean ± s.d., n = 3), respectively, for the Tol2-mediated gene transfer samples. We also mapped the transposon integration sites in these T-cells (day 29) by inverse PCR, as well as the integration sites of CD19-CAR T-cells generated by the retrovirus system in our previous study 15 as a control (Table 1) . These results indicate that the Tol2 transposon integrated into the human genome and stably expressed CD19-CAR in primary human T-cells.
We next assessed antigen-dependent IFN-γ production of Tol2-engineered T-cells by enzyme-linked immunosorbent assay and found that they selectively produced IFN-γ only in response to CD19 + target cells (Figure 3a ). CD19-CAR T-cells showed cell lytic activity against Raji cells but not against control CD19-negative K562 cells (Figure 3b) . We then examined which subpopulations of T-cells were involved in targeted cell killing by cell fractionation. Both CD4 + -and CD8 + -sorted T-cells specifically lysed CD19 + target cells. However, CD4
+ T-cell-mediated cytotoxicity was about twofold less than that observed for CD8 + T-cells ( Figure 3c ). Moreover, CD4
+ and CD8 + T-cells also killed primary CD19 + B-cell lymphoma cells isolated from a patient with a diffuse large B-cell lymphoma ( Figure 3d ). Taken together, these results demonstrate that expanded CD19-CAR T-cells exhibited CD19-dependent effector functions in vitro.
We next wanted to evaluate the in vivo anti-tumor effects of engineered T-cells in a mouse xenograft model that we previously established. 15 Rag2 − / − γc − / − immunodeficient mice were intravenously injected with luciferase-expressing Raji cells. Three days later, the mice were intravenously injected with CD19-CAR T-cells. Bioluminescent imaging revealed that CD19-CAR T-cells successfully suppressed Raji tumor progression, while Raji tumors grew systemically in the untreated group (Figure 4a ). To augment these in vivo findings, we evaluated treatment with an antibody against the programmed death (PD)-1 protein, because our expanded T-cells partially expressed PD-1 (23 ± 6.2%; mean ± s.d., n = 3) and a PD-1 blockade by the antibody previously enhanced the antitumor activity of PD-1 + tumor-or virus-specific T-cells in vivo. 16 We found that use of the anti-PD-1 antibody did not significantly reduce the number of tumors at the day 27 end point compared with the T-cell group alone (P = 0.30) (Figures 4a and b) . However, two of the four animals treated with the anti-PD-1 antibody were tumor free, while all three mice in the T-cell group carried tumors. These observations do not support those of John et al., 17 who previously demonstrated that treatment with an anti-PD-1 antibody augmented the anti-tumor activity of PD-1 + Her-2-specific CAR T-cells cultured with antigen stimulation in their mouse model of Her-2 + breast cancer. It is possible that the types of tumors, levels of PD-1 and use of immunocompetent or immunocompromised animals in these different studies may account for these observed differences. Neither nontransduced T-cells nor the PD-1 antibody injection alone suppressed tumor progression in our present study (data not shown).
We next examined whether interleukin (IL)-7 could improve the in vivo efficacy of these T-cells in our mouse model, because IL-7 has been used to augment the anti-tumor effects of antigenspecific T-cells after adoptive cell therapy in mouse models. 18 We used the adeno-associated virus (AAV) vector system to achieve systemic and long-term IL-7 expression in mice. 19 The IL-7+ T-cell group showed enhanced tumor suppression via imaging analysis compared with that of the control group (P = 0.001) and approached statistical significance compared with that of the T-cell transfer group alone (P = 0.12, Figures 4c and d) . AAVmediated IL-7 administration alone did not suppress tumor growth (data not shown). These results show that Tol2-engineered T-cells function as anti-tumor effector cells in our mouse model.
CAR-based T-cell therapy is dependent on efficient gene transfer and an optimal expansion regimen to achieve both the cell number and potency required for use in the clinical setting. One day after nucleofection, expression of CD19-CAR was 24% in CD3 + Tol2-engineered T-cells (Figure 2a, upper) , which is similar to the transgene expression previously observed in Figure 1 . CD19-CAR and the Tol2 transposon system used in this study. VH, variable heavy chain; VL, variable light chain; hatched box, CD8α signal peptide; black box, (GGGGS) 3 linker; pTol2-CD19-CAR, Tol2 transposon plasmid carrying CD19-CAR; CAGp, hybrid cytomegalovirus enhancer/chicken β-actin promoter; TIR, terminal inverted repeat; pCAGGS-mT2TP, Tol2 transposase (TPase) expression plasmid. Distance from the transcription start site or end sites of RefSeq genes is indicated.
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CD3
+ SB-engineered T-cells (19-65%; day 1). 13, 20 After 3 weeks of expansion, stable and robust CD19-CAR expression was detected in engineered T-cells (~95%; Figure 2a , lower), comparable to that observed in SB-or PB-engineered T-cells with CD19-CAR (51-98%) after 3 weeks of expansion with antigen stimulation. 10, 13, 20 Improvements in vector design and delivery should yield even better results. Peng et al. 21 showed that a green fluorescent protein (GFP)-encoded SB transposon exhibited 450% transduction without antigen stimulation in primary T-cells in the presence of an mRNA-encoded transposase. Additionally, SB100X, which encodes a hyperactive SB transposase, exhibited improved transposition activity and enhanced T-cell gene transfer efficiency. 22 Thus future development of the hyperactive Tol2 transposase and its RNA delivery may improve the generation of CD19-CAR T-cells.
Some retroviral vectors integrate near transcription start sites and so have the potential to cause insertional mutagenesis. 23 However, as yet there have been no reports that retroviral vectors have caused adverse events in T-cells. 24 Tol2 transposons preferentially integrate around transcription start sites, CpG islands and DNaseI hypersensitive sites. 25 We mapped the integration sites of Tol2-and retrovirus vector-engineered T-cells with CD19-CAR and showed that their target sequences did not overlap (Table 1) . However, our sample size is too small to compare the exact integration profile of each vector, so further large-scale comparative analysis of integration sites will provide the necessary important information about the integration preference and safety of the vectors. Regardless of the vector system used, the development of safer transgene delivery systems has become an important area of study. To this end, AAV-based site-directed integration systems may be useful, because Rep proteins from AAV facilitate the integration of the viral genome into a specific locus (termed AAVS1) in chromosome 19. 26 This locus is one of the safe locations in the human genome for efficient and safe transgene expression. 27 Ammar et al.
28
demonstrated that fusion constructs consisting of Rep and Tol2 transposase integrated marker genes from Tol2 transposon donor plasmids near the AAVS1 locus, which may offer a safer transposon-based gene delivery system for human gene and cell therapy.
In the present study, we have demonstrated that the adoptive transfer of Tol2-engineered T-cells with CD19-CAR suppressed tumor growth in tumor-bearing mice and have shown enhanced tumor suppression of Tol2-engineered T-cells in combination with systemic IL-7 delivery. IL-7 has previously been used to enhance the anti-tumor effect of tumor specific-T-cells in preclinical and clinical studies and has acceptable toxicity profiles. 18 Furthermore, IL-7 preferentially maintains memory CD4 + and CD8 + T-cells over CD4 +
CD25
+ Foxp3 + regulatory T-cells in clinical trials. 18 Therefore, IL-7 appears to be a potential adjuvant for engineered T-cell therapy.
The Tol2 transposon system is a promising technology for gene transfer in mammalian cells, and its efficacy is comparable with other transposon systems, such as SB and PB transposons. Tol2 also offers some advantages over SB, including a high cargo capacity and limited OPI, which are important characteristics for transposon-based gene therapy. With respect to cargo capacity and OPI, PB is similar to Tol2. Therefore, the simultaneous comparison of Tol2 and PB, with or without various augmenting reagents (for example, PD-1 antibody or IL-7) in a characterized mouse model as described in this work, would help identify an optimal transposon system for immunogene therapy.
In conclusion, we used the Tol2 transposon system to stably transfer CD19-CAR into primary human T-cells. We found that expanded T-cells contained one or two copies of CD19-CAR leading to efficient transgene expression and further 
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T Tsukahara et al demonstrated that they exhibited CD19-dependent anti-tumor effects in vitro and in a xenograft mouse model of human B-cell lymphoma. Our results indicate that the Tol2 transposon system is a useful gene transfer platform and could be applied to CD19-CAR-based T-cell therapy for refractory B-cell malignancies.
MATERIALS AND METHODS
Plasmids
The Tol2 transposon plasmid pT2AL200R175-CAGGS-EGFP has been described previously. 7 The Tol2 transposon plasmid encoding CD19-specific CAR with CD28 and CD3ζ signaling domains (CD19-CAR) from the SFG-1928z retroviral vector 29 pTol2-CD19-CAR was generated by replacing the EGFP sequence of pT2AL200R175-CAGGS-EGFP with the CD19-CAR sequence. The Tol2-transposase plasmid pCAGGS-mT2TP carrying a modified transposase cDNA 5 with codons optimized for mammalian use was also transfected. The human IL-7 expression vector AAV-IL-7 was generated by ligating IL-7 cDNA into the pAAV-MCS vector (Agilent Technologies Inc., Palo Alto, CA, USA).
Recombinant AAV-IL-7 production The recombinant AAV-IL-7 vector (serotype 1) was prepared as previously described, 30 and vector titers were measured using real-time PCR. 30 PBLs and cell lines PBLs from three healthy donors and a clinical sample from a patient with non-Hodgkin B-cell lymphoma were collected under a protocol approved by the Jichi Medical University Institutional Review Board, with written informed consent obtained from each donor. The mouse fibroblast NIH3T3 cell line expressing human CD19 (3T3/CD19) 31 was maintained in Dulbecco's modified Eagle's medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA). The human Burkitt lymphoma cell line Raji (Health Science Research Resources Bank, Osaka, Japan), Raji cells expressing luciferase (Raji/Luc) 15 and the human erythroleukemia cell line K562 (Riken BRC, Ibaraki, Japan) were also used. Cell lines were cultured in RPMI 1640 medium (Life Technologies) supplemented with 10% fetal bovine serum.
Transfection and expansion of T-cells PBLs (5 × 10 6 ) were nucleofected with pTol2-CD19-CAR and pCAGGS-mT2TP (5 μg each) using the Human T-cell Nucleofector Kit and Amaxa Nucleofector II program U-014 (Lonza, Basel, Switzerland) on day 0. Transfected PBLs were transferred to X-Vivo 15 (Takara Bio, Shiga, Japan) supplemented with 5% human AB serum (NOVA Biologics, Oceanside, CA, USA) (T-cell complete medium) and cultured overnight. The next day, cells were stimulated with γ-irradiated (50 Gy) 3T3/CD19 cells at a 1:1 ratio Flow cytometry CD19-CAR surface expression on transduced T-cells was assessed using a biotin goat anti-mouse F(ab′)-specific antibody, phycoerythrin-Streptavidin (Jackson Immunoresearch, West Grove, PA, USA) and fluorescein isothiocyanate anti-human CD3 (Biolegend, San Diego, CA, USA). Samples were analyzed using the BD LSR Fortessa with FACSDiva software (BD Biosciences, San Diego, CA, USA).
Western blotting CD19-CAR protein expression was examined by western blotting using an anti-human CD3ζ antibody as described previously. 15 Transgene copy number and integration sites Transgene copy numbers were measured by real-time quantitative PCR using Thermal Cycler Dice Real Time System II (Takara Bio). Genomic DNA was isolated from CD19-CAR T-cells by a QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) on days 21 and 29 after transduction. PCR was performed using a Cycleave PCR Core kit (Takara Bio) with sets of primers and probes specific for CD19-CAR and human IFN-γ. For CD19-CAR, these were the forward primer A: 5′-TGCACAGTGACTACATGAACA-3′; the reverse primer B: 5′-CGTC CTAGATTGAGCTCGTTA-3′; and probe: 5′-gctcc(A)gag-3′; for IFN-γ, these were the forward primer C: 5′-CAGGGTCACCTGACACATTCA-3′; the reverse primer D: 5′-ACTAGGCAGCCAACCTAAGC-3′; and probe: 5′-acaatgaac(A)ct-3′. Uppercase letters of probe sequences represent RNA bases. Serially diluted CD19-CAR and human IFN-γ plasmid standards (1 μl containing 6 × 10 1 -3 × 10 6 copies each) were used. Each standard curve (threshold cycle values versus copy numbers) is shown in Supplementary Figure S2 (day 29) . The average CD19-CAR copy number per cell was calculated by normalizing to the endogenous number of diploid human IFN-γ copies.
Inverse PCR was performed as described previously 7 to identify the 3′ transposon junction sequence. Genomic DNA was digested with Hpa II and self-ligated. Integration junction sequences were amplified by two rounds of PCR. The primers for first-round PCR were: F1 (5′-TGGCGGCCTCGAGTGGCTGTTA-3′) and R1 (5′-CTCTA CAAATGTGGTATGGCTG-3′); those for second-round PCR were: F2 (5′-GTGAAGGGCGTCGTAGGTGTC-3′) and R2 (5′-GTATGGCTGATT ATGATCCTCTA-3′). Second-round PCR products were cloned into a pMD20-T vector (Takara Bio), which was then transformed into DH5α cells. The genomic integration sites of retrovirus vectors were determined in our previous study. 32 Sequences of resulting clones were subjected to a human BLAST search at http://blast. ncbi.nlm.nih.gov/Blast.cgi and analyzed as described previously. 32 Enzyme-linked immunosorbent assay Supernatants from duplicate wells of the target 3T3/CD19 cell and effector CD19-CAR T-cell co-culture (10 5 cells each) were harvested after 48-h incubation. Supernatant human IFN-γ levels were measured using a human IFN-γ enzyme-linked immunosorbent assay kit (Biolegend).
Cytotoxicity assay Cell lytic activity was examined using calcein acetoxymethyl ester (Calcein-AM) (Dojindo, Kumamoto, Japan) cytotoxicity assays. 33 Calcein-AM-labeled Raji cells and K562 target cells (10 4 each) were co-cultured with increasing numbers of effector CD19-CAR T-cells. [35] [36] [37] were intravenously injected with 5 × 10 4 Raji/Luc cells on day 0. Mice were intravenously injected with 10 7 CD19-CAR T-cells alone on day 3 or T-cells in combination with either intraperitoneal injection of an anti-PD-1 antibody (Clone J116; Bio-XCell, West Lebanon, NH, USA) 38 at 250 μg per mouse (on days 3, 10 and 17) or intramuscular injection of AAV-IL-7 (10 11 vg per body) on day 3. 19 Bioluminescence imaging was performed and analyzed using an IVIS imaging system with the Living Image software (PerkinElmer, Waltham, MA, USA) as described previously. 15 All mouse experiments were carried out humanely following approval from the Institutional Animal Experiment Committee of Jichi Medical University.
Statistical analysis
The Student's t-test was used to evaluate differences in experiments. GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) was used to analyze statistical calculations. A value of Po 0.05 was considered statistically significant.
Nucleotide sequence accession numbers Reported nucleotide sequence data are available from the DDBJ/EMBL/GenBank database under accession nos. AB917147-AB917152 and LC002285-LC002289.
